{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:18:10Z","timestamp":1784557090551,"version":"3.55.0"},"reference-count":35,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["etj.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,18]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The aim was to determine the combined value of serological lipid metabolism and an orbital MRI quantitative parameter in predicting the effectiveness of glucocorticoid (GC) therapy in patients with thyroid eye disease (TED).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study retrospectively enrolled 46 patients with active and moderate-to-severe TED (GC-effective group,\n                      <jats:italic>n<\/jats:italic>\n                      = 29; GC-ineffective group,\n                      <jats:italic>n<\/jats:italic>\n                      = 17). Serological lipid metabolism, the orbital MRI-based minimum signal intensity ratio of extraocular muscles (EOM-SIR\n                      <jats:sub>min<\/jats:sub>\n                      ), as well as other clinical parameters before GC therapy were collected and compared between the two groups. Multivariate logistic regression and receiver operating characteristic curve analysis were adopted to identify independent predictable variables and assess their predictive performances.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared to the GC-ineffective group, the GC-effective group showed lower serum total cholesterol levels (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.006), lower serum low-density lipoprotein cholesterol levels (\n                      <jats:italic>P\u2009=\u2009<\/jats:italic>\n                      0.019), higher EOM-SIR\n                      <jats:sub>min<\/jats:sub>\n                      values (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.005), and shorter disease durations (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.017). Serum total cholesterol and EOM-SIR\n                      <jats:sub>min<\/jats:sub>\n                      were found to be independent predictors of GC-effective TED through multivariate analysis (odds ratios\u2009=\u20090.253 and 2.036 per 0.1 units, respectively) (both\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05). The integration of serum total cholesterol \u22644.8 mmol\/L and EOM-SIR\n                      <jats:sub>min<\/jats:sub>\n                      \u2265 1.12 had a better predictive efficacy (area under the curve, 0.834) than EOM-SIR\n                      <jats:sub>min<\/jats:sub>\n                      alone, with a sensitivity of 75.9% and a specificity of 82.4% (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.031).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Serological lipid metabolism, combined with an orbital MRI-derived parameter, was a useful marker for predicting the effectiveness of GCs in patients with active and moderate-to-severe TED.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-23-0109","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T12:45:48Z","timestamp":1705581948000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-16","source":"Crossref","is-referenced-by-count":10,"title":["Predicting glucocorticoid effectiveness in thyroid eye disease: combined value from serological lipid metabolism and an orbital MRI parameter"],"prefix":"10.1530","volume":"13","author":[{"given":"Haitao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjie","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Friendship Hospital of Ili Kazakh Autonomous Prefecture Ili & Jiangsu Joint Institute of Health, Ili, China"},{"name":"Department of Ophthalmology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoquan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0201-2059","authenticated-orcid":true,"given":"Huanhuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"New England Journal of Medicine","first-page":"726","article-title":"Graves' ophthalmopathy","volume":"362","author":"Bahn","year":"2010","unstructured":"Bahn RS. Graves' ophthalmopathy. New England Journal of Medicine2010362726\u2013738. (https:\/\/doi.org\/10.1056\/NEJMra0905750)"},{"key":"bib2","series-title":"Current Eye Research","first-page":"1325","article-title":"Clinical management and therapeutic strategies for the thyroid-associated ophthalmopathy: current and future perspectives","volume":"45","author":"Mishra","year":"2020","unstructured":"Mishra SMaurya VKKumar SAnkita KAKaur A & Saxena SK. Clinical management and therapeutic strategies for the thyroid-associated ophthalmopathy: current and future perspectives. Current Eye Research2020451325\u20131341. (https:\/\/doi.org\/10.1080\/02713683.2020.1776331)"},{"key":"bib3","series-title":"Internal Medicine","first-page":"353","article-title":"Graves' ophthalmopathy: epidemiology and natural history","volume":"53","author":"Hiromatsu","year":"2014","unstructured":"Hiromatsu YEguchi HTani JKasaoka M & Teshima Y. Graves' ophthalmopathy: epidemiology and natural history. Internal Medicine201453353\u2013360. (https:\/\/doi.org\/10.2169\/internalmedicine.53.1518)"},{"key":"bib4","series-title":"Frontiers in Endocrinology","first-page":"615993","article-title":"Epidemiology, natural history, risk factors, and prevention of Graves' orbitopathy","volume":"11","author":"Bartalena","year":"2020","unstructured":"Bartalena LPiantanida EGallo DLai A & Tanda ML. Epidemiology, natural history, risk factors, and prevention of Graves' orbitopathy. Frontiers in Endocrinology202011615993. (https:\/\/doi.org\/10.3389\/fendo.2020.615993)"},{"key":"bib5","series-title":"British Journal of Ophthalmology","first-page":"142","article-title":"Pathogenesis of thyroid eye disease: review and update on molecular mechanisms","volume":"100","author":"Khong","year":"2016","unstructured":"Khong JJMcnab AAEbeling PRCraig JE & Selva D. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. British Journal of Ophthalmology2016100142\u2013150. (https:\/\/doi.org\/10.1136\/bjophthalmol-2015-307399)"},{"key":"bib6","series-title":"European Journal of Endocrinology","first-page":"G43","article-title":"The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy","volume":"185","author":"Bartalena","year":"2021","unstructured":"Bartalena LKahaly GJBaldeschi LDayan CMEckstein AMarcocci CMarin\u00f2 MVaidya B & Wiersinga WM. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. European Journal of Endocrinology2021185G43\u2013G67. (https:\/\/doi.org\/10.1530\/EJE-21-0479)"},{"key":"bib7","series-title":"Ophthalmic Plastic and Reconstructive Surgery","first-page":"162","article-title":"Treatment of active corticosteroid-resistant graves' orbitopathy","volume":"30","author":"P\u00e9rez-Moreiras","year":"2014","unstructured":"P\u00e9rez-Moreiras JVAlvarez-L\u00f3pez A & G\u00f3mez EC. Treatment of active corticosteroid-resistant graves' orbitopathy. Ophthalmic Plastic and Reconstructive Surgery201430162\u2013167. (https:\/\/doi.org\/10.1097\/IOP.0000000000000037)"},{"key":"bib8","series-title":"European Journal of Endocrinology","first-page":"55","article-title":"The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor","volume":"170","author":"Vannucchi","year":"2014","unstructured":"Vannucchi GCovelli DCampi IOrigo DCurr\u00f2 NCirello VDazzi DBeck-Peccoz P & Salvi M. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor. European Journal of Endocrinology201417055\u201361. (https:\/\/doi.org\/10.1530\/EJE-13-0611)"},{"key":"bib9","series-title":"Thyroid Research","first-page":"13","article-title":"Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves' orbitopathy","volume":"12","author":"Walasik-Szempli\u0144ska","year":"2019","unstructured":"Walasik-Szempli\u0144ska DKami\u0144ski G & Sudo\u0142-Szopi\u0144ska I. Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves' orbitopathy. Thyroid Research20191213. (https:\/\/doi.org\/10.1186\/s13044-019-0074-0)"},{"key":"bib10","series-title":"Seminars in Cell and Developmental Biology","first-page":"97","article-title":"Significance and regulation of lipid metabolism","volume":"81","author":"Debose-Boyd","year":"2018","unstructured":"Debose-Boyd RA. Significance and regulation of lipid metabolism. Seminars in Cell and Developmental Biology20188197. (https:\/\/doi.org\/10.1016\/j.semcdb.2017.12.003)"},{"key":"bib11","series-title":"Frontiers in Endocrinology","first-page":"933","article-title":"Cholesterol serum levels and use of statins in Graves' orbitopathy: a new starting point for the therapy","volume":"10","author":"Lanzolla","year":"2019","unstructured":"Lanzolla GVannucchi GIonni ICampi ISileo FLazzaroni E & Marin\u00f2 M. Cholesterol serum levels and use of statins in Graves' orbitopathy: a new starting point for the therapy. Frontiers in Endocrinology201910933. (https:\/\/doi.org\/10.3389\/fendo.2019.00933)"},{"key":"bib12","series-title":"Journal of Endocrinological Investigation","first-page":"1417","article-title":"Relationship between serum cholesterol and Graves' orbitopathy (GO): a confirmatory study","volume":"41","author":"Lanzolla","year":"2018","unstructured":"Lanzolla GSabini EProfilo MAMazzi BSframeli ARocchi RMenconi FLeo MNardi MVitti P, et al.Relationship between serum cholesterol and Graves' orbitopathy (GO): a confirmatory study. Journal of Endocrinological Investigation2018411417\u20131423. (https:\/\/doi.org\/10.1007\/s40618-018-0915-z)"},{"key":"bib13","series-title":"Thyroid","first-page":"386","article-title":"High serum cholesterol is a novel risk factor for Graves' orbitopathy: results of a cross-sectional study","volume":"28","author":"Sabini","year":"2018","unstructured":"Sabini EMazzi BProfilo MAMautone TCasini GRocchi RIonni IMenconi FLeo MNardi M, et al.High serum cholesterol is a novel risk factor for Graves' orbitopathy: results of a cross-sectional study. Thyroid201828386\u2013394. (https:\/\/doi.org\/10.1089\/thy.2017.0430)"},{"key":"bib14","series-title":"Frontiers in Endocrinology","first-page":"609895","article-title":"Evidence that baseline levels of low-density lipoproteins cholesterol affect the clinical response of graves' ophthalmopathy to parenteral corticosteroids","volume":"11","author":"Naselli","year":"2020","unstructured":"Naselli AMoretti DRegalbuto CArpi MLLo Giudice FFrasca FBelfiore A & Le Moli R. Evidence that baseline levels of low-density lipoproteins cholesterol affect the clinical response of graves' ophthalmopathy to parenteral corticosteroids. Frontiers in Endocrinology202011609895. (https:\/\/doi.org\/10.3389\/fendo.2020.609895)"},{"key":"bib15","series-title":"Japanese Journal of Ophthalmology","first-page":"430","article-title":"Changes of orbital tissue volumes and proptosis in patients with thyroid extraocular muscle swelling after methylprednisolone pulse therapy","volume":"59","author":"Higashiyama","year":"2015","unstructured":"Higashiyama TNishida Y & Ohji M. Changes of orbital tissue volumes and proptosis in patients with thyroid extraocular muscle swelling after methylprednisolone pulse therapy. Japanese Journal of Ophthalmology201559430\u2013435. (https:\/\/doi.org\/10.1007\/s10384-015-0410-4)"},{"key":"bib16","series-title":"Endocrine","first-page":"372","article-title":"Predicting the response to glucocorticoid therapy in thyroid-associated ophthalmopathy: mobilizing structural MRI-based quantitative measurements of orbital tissues","volume":"70","author":"Hu","year":"2020","unstructured":"Hu HXu XQChen LChen WWu QChen HHZhu HShi HB & Wu FY. Predicting the response to glucocorticoid therapy in thyroid-associated ophthalmopathy: mobilizing structural MRI-based quantitative measurements of orbital tissues. Endocrine202070372\u2013379. (https:\/\/doi.org\/10.1007\/s12020-020-02367-5)"},{"key":"bib17","series-title":"Journal of Magnetic Resonance Imaging","first-page":"862","article-title":"T(2) -Weighted MR imaging-derived Radiomics for pretreatment determination of therapeutic response to glucocorticoid in patients with thyroid-associated ophthalmopathy: comparison with semiquantitative evaluation","volume":"56","author":"Hu","year":"2022","unstructured":"Hu HChen LZhang JLChen WChen HHLiu HShi HBWu FY & Xu XQ. T(2) -Weighted MR imaging-derived Radiomics for pretreatment determination of therapeutic response to glucocorticoid in patients with thyroid-associated ophthalmopathy: comparison with semiquantitative evaluation. Journal of Magnetic Resonance Imaging202256862\u2013872. (https:\/\/doi.org\/10.1002\/jmri.28088)"},{"key":"bib18","series-title":"American Journal of Ophthalmology","first-page":"792","article-title":"Diagnostic criteria for Graves' ophthalmopathy","volume":"119","author":"Bartley","year":"1995","unstructured":"Bartley GB & Gorman CA. Diagnostic criteria for Graves' ophthalmopathy. American Journal of Ophthalmology1995119792\u2013795. (https:\/\/doi.org\/10.1016\/S0002-9394(1472787-4)"},{"key":"bib19","series-title":"European Thyroid Journal","first-page":"9","article-title":"The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy Guidelines for the Management of Graves\u2019 Orbitopathy","volume":"5","author":"Bartalena","year":"2016","unstructured":"Bartalena LBaldeschi LBoboridis KEckstein AKahaly GJMarcocci CPerros PSalvi M & Wiersinga WM. The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy Guidelines for the Management of Graves\u2019 Orbitopathy. European Thyroid Journal201659\u201326. (https:\/\/doi.org\/10.1159\/000443828)"},{"key":"bib20","series-title":"Clinical Endocrinology","first-page":"9","article-title":"Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy","volume":"47","author":"Mourits","year":"1997","unstructured":"Mourits MPPrummel MFWiersinga WM & Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clinical Endocrinology1997479\u201314. (https:\/\/doi.org\/10.1046\/j.1365-2265.1997.2331047.x)"},{"key":"bib21","series-title":"International Journal of Endocrinology","first-page":"3196059","article-title":"Thickness of extraocular muscle and orbital fat in MRI predicts response to glucocorticoid therapy in graves' ophthalmopathy","volume":"2017","author":"Xu","year":"2017","unstructured":"Xu LLi LXie CGuan M & Xue Y. Thickness of extraocular muscle and orbital fat in MRI predicts response to glucocorticoid therapy in graves' ophthalmopathy. International Journal of Endocrinology201720173196059. (https:\/\/doi.org\/10.1155\/2017\/3196059)"},{"key":"bib22","series-title":"Endocrine","first-page":"445","article-title":"Circulating microRNA predicts insensitivity to glucocorticoid therapy in Graves' ophthalmopathy","volume":"49","author":"Shen","year":"2015","unstructured":"Shen LHuang FYe LZhu WZhang XWang SWang W & Ning G. Circulating microRNA predicts insensitivity to glucocorticoid therapy in Graves' ophthalmopathy. Endocrine201549445\u2013456. (https:\/\/doi.org\/10.1007\/s12020-014-0487-4)"},{"key":"bib23","series-title":"Clinical Endocrinology","first-page":"175","article-title":"Factors associated with the efficacy of intravenous methylprednisolone in moderate-to-severe and active thyroid-associated ophthalmopathy: a single-centre retrospective study","volume":"90","author":"Hu","year":"2019","unstructured":"Hu SWang YHe MZhang MDing X & Shi B. Factors associated with the efficacy of intravenous methylprednisolone in moderate-to-severe and active thyroid-associated ophthalmopathy: a single-centre retrospective study. Clinical Endocrinology201990175\u2013183. (https:\/\/doi.org\/10.1111\/cen.13855)"},{"key":"bib24","series-title":"Korean Journal of Radiology","first-page":"664","article-title":"T2 mapping with and without fat-suppression to predict treatment response to intravenous glucocorticoid therapy for thyroid-associated ophthalmopathy","volume":"23","author":"Zhai","year":"2022","unstructured":"Zhai LWang QLiu PLuo BYuan G & Zhang J. T2 mapping with and without fat-suppression to predict treatment response to intravenous glucocorticoid therapy for thyroid-associated ophthalmopathy. Korean Journal of Radiology202223664\u2013673. (https:\/\/doi.org\/10.3348\/kjr.2021.0627)"},{"key":"bib25","series-title":"Frontiers in Endocrinology","first-page":"614536","article-title":"Baseline volumetric T2 relaxation time histogram analysis: can it be used to predict the response to intravenous methylprednisolone therapy in patients with thyroid-associated ophthalmopathy?","volume":"12","author":"Liu","year":"2021","unstructured":"Liu PLuo BChen LWang QXYuan GJiang GH & Zhang J. Baseline volumetric T2 relaxation time histogram analysis: can it be used to predict the response to intravenous methylprednisolone therapy in patients with thyroid-associated ophthalmopathy?Frontiers in Endocrinology202112614536. (https:\/\/doi.org\/10.3389\/fendo.2021.614536)"},{"key":"bib26","series-title":"Clinical Radiology","first-page":"159.e1","article-title":"T2 mapping histogram at extraocular muscles for predicting the response to glucocorticoid therapy in patients with thyroid-associated ophthalmopathy","volume":"76","author":"Hu","year":"2021","unstructured":"Hu HChen H-HChen WWu QChen LZhu HXu X-QShi H-B & Wu F-Y. T2 mapping histogram at extraocular muscles for predicting the response to glucocorticoid therapy in patients with thyroid-associated ophthalmopathy. Clinical Radiology202176159.e1\u2013159.e8. (https:\/\/doi.org\/10.1016\/j.crad.2020.09.005)"},{"key":"bib27","series-title":"European Journal of Radiology","first-page":"109839","article-title":"Prediction of treatment response to intravenous glucocorticoid in patients with thyroid-associated ophthalmopathy using T2 mapping and T2 IDEAL","volume":"142","author":"Zhai","year":"2021","unstructured":"Zhai LLuo BWu HWang QYuan GLiu PMa YZhao Y & Zhang J. Prediction of treatment response to intravenous glucocorticoid in patients with thyroid-associated ophthalmopathy using T2 mapping and T2 IDEAL. European Journal of Radiology2021142109839. (https:\/\/doi.org\/10.1016\/j.ejrad.2021.109839)"},{"key":"bib28","series-title":"Journal of Neuro-Ophthalmology","first-page":"186","article-title":"Thyroid eye disease: therapy in the active phase","volume":"34","author":"Bhatti","year":"2014","unstructured":"Bhatti MT & Dutton JJ. Thyroid eye disease: therapy in the active phase. Journal of Neuro-Ophthalmology201434186\u2013197. (https:\/\/doi.org\/10.1097\/WNO.0000000000000128)"},{"key":"bib29","series-title":"PLoS One","first-page":"e80588","article-title":"Diet induced mild hypercholesterolemia in pigs: local and systemic inflammation, effects on vascular injury - rescue by high-dose statin treatment","volume":"8","author":"Busnelli","year":"2013","unstructured":"Busnelli MManzini SFroio AVargiolu ACerrito MGSmolenski RTGiunti MCinti AZannoni ALeone BE, et al.Diet induced mild hypercholesterolemia in pigs: local and systemic inflammation, effects on vascular injury - rescue by high-dose statin treatment. PLoS One20138e80588. (https:\/\/doi.org\/10.1371\/journal.pone.0080588)"},{"key":"bib30","series-title":"JAMA Ophthalmology","first-page":"290","article-title":"Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease","volume":"133","author":"Stein","year":"2015","unstructured":"Stein JDChilders DGupta STalwar NNan BLee BJSmith TJ & Douglas R. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmology2015133290\u2013296. (https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.5103)"},{"key":"bib31","series-title":"Journal of Neuro-Ophthalmology","first-page":"177","article-title":"The pathophysiology of thyroid eye disease","volume":"34","author":"Shan","year":"2014","unstructured":"Shan SJ & Douglas RS. The pathophysiology of thyroid eye disease. Journal of Neuro-Ophthalmology201434177\u2013185. (https:\/\/doi.org\/10.1097\/WNO.0000000000000132)"},{"key":"bib32","series-title":"Frontiers in Endocrinology","first-page":"607968","article-title":"Simvastatin and ROCK inhibitor Y-27632 inhibit myofibroblast differentiation of graves' ophthalmopathy-derived orbital fibroblasts via RhoA-mediated ERK and p38 signaling pathways","volume":"11","author":"Wei","year":"2020","unstructured":"Wei YHLiao SLWang SHWang CC & Yang CH. Simvastatin and ROCK inhibitor Y-27632 inhibit myofibroblast differentiation of graves' ophthalmopathy-derived orbital fibroblasts via RhoA-mediated ERK and p38 signaling pathways. Frontiers in Endocrinology202011607968. (https:\/\/doi.org\/10.3389\/fendo.2020.607968)"},{"key":"bib33","series-title":"Endocrine Connections","first-page":"1230","article-title":"Simvastatin downregulates adipogenesis in 3T3-L1 preadipocytes and orbital fibroblasts from Graves' ophthalmopathy patients","volume":"8","author":"Shahida","year":"2019","unstructured":"Shahida BJohnson PSJain RBrorson H\u00c5sman PLantz M & Planck T. Simvastatin downregulates adipogenesis in 3T3-L1 preadipocytes and orbital fibroblasts from Graves' ophthalmopathy patients. Endocrine Connections201981230\u20131239. (https:\/\/doi.org\/10.1530\/EC-19-0319)"},{"key":"bib34","series-title":"The Lancet Diabetes and Endocrinology","first-page":"733","article-title":"Statins for Graves' orbitopathy (Stago): a phase 2, open-label, adaptive, single centre, randomised clinical trial","volume":"9","author":"Lanzolla","year":"2021","unstructured":"Lanzolla GSabini ELeo MMenconi FRocchi RSframeli APiaggi PNardi MMarcocci C & Marin\u00f2 M. Statins for Graves' orbitopathy (Stago): a phase 2, open-label, adaptive, single centre, randomised clinical trial. The Lancet Diabetes and Endocrinology20219733\u2013742. (https:\/\/doi.org\/10.1016\/S2213-8587(2100238-2)"},{"key":"bib35","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"e2819","article-title":"Statins: a New Hope on the horizon of graves orbitopathy?","volume":"106","author":"Marin\u00f2","year":"2021","unstructured":"Marin\u00f2 MLanzolla G & Marcocci C. Statins: a New Hope on the horizon of graves orbitopathy?Journal of Clinical Endocrinology and Metabolism2021106e2819\u2013e2821. (https:\/\/doi.org\/10.1210\/clinem\/dgab184)"}],"container-title":["European Thyroid Journal"],"original-title":[],"link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/13\/1\/ETJ-23-0109.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/13\/1\/ETJ-23-0109.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/13\/1\/ETJ-23-0109.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:51:49Z","timestamp":1784555509000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/etj\/article\/2974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":35,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/etj-23-0109","relation":{},"ISSN":["2235-0802"],"issn-type":[{"value":"2235-0802","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]}}}